Kymera completes enrollment in Phase 2b KT-621 AD trial; topline data accelerated to year-end 2026

Kymera Therapeutics, Inc.

Enrollment in BROADEN2 completed nearly six months ahead of schedule; topline data now expected by year-end 2026.
Phase 3 trials in atopic dermatitis planned to initiate by mid-2027, subject to regulatory discussions.
BROADEN2 is a randomized, double-blind, placebo-controlled trial in ~200 patients ages 12-75 over 16 weeks.
KT-621 also in BREADTH Phase 2b asthma trial with data expected in late 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.